ATH 0.00% 0.3¢ alterity therapeutics limited

PBT434 inhibits alpha- synuclein in the brain.

  1. 5,921 Posts.
    lightbulb Created with Sketch. 151
    [The findings showed that PBT434 passed the blood-brain barrier and inhibited the alpha-synuclein protein which when aggregated in the brain is a pathological hallmark of Parkinsonian conditions and is considered an important biologic target for treating these neurodegenerative diseases.]
    More info from the P1.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.